Advancing novel immunotherapeutics to treat infectious disease and cancer
Our Product Pipeline
Vaccines for Infectious Disease
We are developing PIKA-based vaccines to prevent or treat infectious disease, including COVID 19, hepatitis B, rabies and flu.
Read More ->
Immuno-Oncology Therapeutics
Our PIKA-based I-O candidates have shown potent antitumor effects in advanced solid tumors in preclinical studies.
Read More ->
About Us
YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Shingles, influenza, Coronavirus. YS Biopharma operates in China, Singapore, the United States, the United Arab Emirates and the Philippines with over 800 employees and led by a management team that combines rich local expertise and global vision in the vaccine and pharmaceutical industry.
PIKA Technology
Developing Diverse Biotherapeutics Based on TLR3, RIG-I and MDA5 Activation
PIKA technology consists of biologic complexes that incorporate an agonist of multiple pathways of immune signaling: TLR3, RIG-I and MDA5. When delivered with relevant protein-based molecules, PIKA technology is offering a promising platform for the development of a wide variety of novel biotherapeutics as new generation of antiviral vaccines, antiviral therapeutics and anticancer therapeutics.
We are Happy To Connect
